NCT01848925View on ClinicalTrials.gov

Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions
Sickle Cell Disease
Interventions
BIOLOGICAL

SANGUINATE™

40 mg/mL intravenous infusion.

DRUG

Hydroxyurea

Standard of care for Sickle Cell treatment, 15 mg/kg.

Trial Locations (4)

Unknown

Fundacion BIOS, Barranquilla

Hospital Pablo TobinUribe, Medellín

Fundacion Reina Isabel, Santiago de Cali

PAMRI, Panama City

Sponsors
All Listed Sponsors
lead

Prolong Pharmaceuticals

INDUSTRY